-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-22
Saito and colleagues developed an accessible 3D culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into intestinal epithelial cells with enterocyte-associated cytochrome P450 and transporter activities, supporting more human-relevant pharmacokinetic testing.
-
Cy5-UTP for RNA Probe Synthesis & Imaging
2026-09-22
Cy5-UTP enables direct far-red visualization of T7-transcribed RNA for FISH, dual-color arrays, and RNA-delivery studies. This practical guide connects labeled RNA production with LNP assay design, emphasizing label-density controls, spectral compatibility, and troubleshooting.
-
Cy5-UTP: From RNA Labeling to Translation
2026-09-21
Cy5-UTP connects mechanistic RNA labeling with translational delivery research. This thought-leadership article explains how Cyanine 5-uridine triphosphate supports RNA probe synthesis, how to validate labeled transcripts, and how fluorescence readouts can inform emerging mRNA nanoparticle strategies without overstating analytical evidence.
-
Annexin V Workflows for Apoptosis and PS Binding
2026-09-21
Build more reliable apoptosis assays with a calcium-dependent phosphatidylserine probe that supports flexible labeling, quantitative binding, and competition studies. This guide translates endothelial-cell coagulation findings into practical workflows for cell death research and cancer research while emphasizing controls, storage, and troubleshooting.
-
DAMGO: From Receptor Assay to Pain Circuit
2026-09-20
DAMGO is a selective µ-opioid receptor agonist for connecting receptor-proximal signaling with circuit-level pain phenotypes. This guide explains how to interpret its assay metrics, use it in opioid receptor signaling research, and avoid confusing local MOR activation with systemic analgesia.
-
GSK126: From EZH2 Mechanism to Translational Strategy
2026-09-19
GSK126 connects precise PRC2 inhibition with practical translational strategy, from biomarker-led oncology studies to carefully bounded exploration of EZH2 biology in fragile X syndrome models.
-
I-BET-762 Workflows for BET Inhibitor Research
2026-09-18
I-BET-762 is a selective BET inhibitor for connecting epigenetic control with inflammation, LPS-responsive transcription, and ferroptosis sensitization. This practical guide translates published BRD4 findings into dose-matrix design, orthogonal readouts, and troubleshooting strategies for cancer and inflammatory disease research.
-
In Situ Electroporation for Localized Nucleic Acid Delivery
2026-09-18
The reference study integrates in situ electroporation with electric cell-substrate impedance sensing to deliver DNA, mRNA, siRNA, and aptamers into adherent mammalian cells while monitoring membrane disruption, recovery, and delayed phenotypic effects. This combined platform supports localized gain-of-function and loss-of-function experiments without separating delivery from longitudinal cell-response measurement.
-
Nebivolol Hydrochloride: Assay Specificity
2026-09-17
Nebivolol hydrochloride is a selective β1-adrenoceptor antagonist with a valuable role in assay specificity. This article explains how recent drug-sensitized yeast research can help distinguish β1-adrenergic signaling effects from mTOR pathway activity.
-
NF449 and Selective Platelet P2X1 Blockade
2026-09-17
The reference study established NF449 as a comparatively selective antagonist of platelet P2X1 receptors and connected receptor blockade with reduced platelet activation and thrombosis. Its combined human platelet and mouse experiments also defined an important dose-dependent loss of selectivity, providing both a pharmacological tool and a caution for antithrombotic interpretation.
-
Salvianolic Acid B and LH2 in Pulmonary Fibrosis
2026-09-16
The reference study identifies Salvianolic acid B as an LH2-directed antifibrotic compound that reduces pathological collagen cross-linking and deposition in pulmonary fibrosis models. Its experimental design links LH2 suppression with inhibition of epithelial–mesenchymal transition, fibroblast-to-myofibroblast transition, and Wnt/β-catenin signaling, providing a mechanistic framework for extracellular matrix research.
-
Decitabine Workflows for Cancer Epigenetics
2026-09-16
Decitabine enables controlled DNA hypomethylation experiments that connect tumor suppressor gene reactivation with immune signaling. This guide translates its dose-dependent biology into practical workflows for hematopoietic malignancy research, solid tumor epigenetic studies, and exploratory psoriasis assays.
-
N-Formimidoyl Thienamycin vs β-Lactam Derivatives
2026-09-15
The 1982 study by Cullmann and colleagues systematically compared N-formimidoyl thienamycin (MK0787) with several newer β-lactam agents across resistant gram-negative and gram-positive clinical isolates. Its main contribution was showing broad, often bactericidal activity against difficult gram-negative organisms, including Pseudomonas aeruginosa and Acinetobacter, with activity that was largely independent of β-lactamase production.
-
MALAT1–TDP-43 RNA Regulation and Cell Viability
2026-09-15
The reference study shows that MALAT1 abundance is functionally connected to TDP-43 RNA binding and cell survival, rather than being only a disease-associated correlate. By comparing human cell models under baseline and MPP+ stress, the authors identify context-dependent changes in TDP-43 occupancy of mRNA transcripts and provide a framework for studying noncoding RNA–protein regulation in neurodegeneration.
-
0.4% Trypan Blue Solution: Cell Counting Guide
2026-09-14
0.4% Trypan Blue Solution is an azo dye for cell staining that supports rapid cell viability measurement and live/dead cell discrimination in research cell suspensions. It is suitable for routine counting and cytotoxicity workflows, but not for diagnostic, medical, or apoptosis-specific classification.